Edesa Biotech Inc.’s first-in-class drug candidate, paridiprubart, has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for evaluation in a U.S. government-funded clinical study.   Paridiprubart represents a new class of HDTs that are designed to modulate the body’s immune response when confronted with known or unknown public heal...